Entero Healthcare Solutions Limited has successfully completed its acquisition of a 51.5% majority equity stake in Anand Chemiceutics Private Limited, marking a significant expansion into the high-growth MedTech market. The company announced this development through regulatory filings and a comprehensive press release dated February 09, 2026.

Acquisition Overview

The pharmaceutical distributor has completed the acquisition of a controlling stake in Anand Chemiceutics Private Limited, a leading distributor of diagnostic products and preferred channel partner for global diagnostic and MedTech companies. This transaction was initially announced to the exchanges on November 12, 2025.

Strategic Value and Market Position

Anand Chemiceutics brings over two decades of established trust, legacy, and technical expertise in diagnostic and MedTech products. The company operates a strong pan-India presence with a customer service network spanning more than 1,500 laboratories, hospitals and government institutions. Its specialized capabilities include distribution, marketing, application and service support for diagnostic equipment and reagents including advanced genomics.

Management Commentary

Commenting on the development, Mr. Prabhat Agrawal, MD and CEO of Entero Healthcare, stated: "I am pleased to welcome Anand Chemiceutics to Entero group. Its extensive track record, partnerships with global diagnostics players and expertise in MedTech combined with our distribution reach, capabilities and resources strategically positions us to build scale in this attractive segment."

Mr. Jayesh Sancheti, MD of Anand Chemiceutics, added: "This is more than a partnership — it's the strategic integration of Anand Chemiceutics legacy trust in diagnostics and MedTech distribution with Entero's scale and technology, creating a powerhouse that creates meaningful difference in patients' lifecycle."

Financial Impact and Growth Prospects

With this acquisition, the MedTech segment is expected to contribute more than approximately INR 1,000 Cr in annualised revenue in the next financial year. The transaction aligns with Entero's vision to create an integrated and comprehensive healthcare supply chain solutions provider, leveraging collective distribution strength, partnerships, geographical reach and expertise.

The regulatory filing was signed by Sanu Kapoor, Vice President-General Counsel, Company Secretary & Compliance Officer, confirming compliance with SEBI regulations and successful completion of this strategic acquisition.

Entero Healthcare Solutions Limited has announced an earnings call scheduled for February 07, 2026, to discuss its unaudited financial results for the quarter and nine months ended December 31, 2025. The company informed the BSE and NSE about this development through a regulatory filing dated February 06, 2026, in compliance with Regulation 30 of SEBI's Listing Obligations and Disclosure Requirements.

Management Participation

The earnings call will feature senior management representatives who will engage with analysts and investors to discuss the company's Q3FY26 performance. The management team participating in the call includes key leadership positions across different operational areas.

Call Details and Access

DAM Capital Advisors Ltd will host the post-results conference call, with Nitin Agarwal serving as the lead analyst. The call will be accessible through multiple dial-in options to accommodate participants from various networks and countries.

International Participation

The earnings call has been scheduled to accommodate international participants across different time zones. The company has provided specific timing details for major international markets to ensure global investor participation.

Regulatory Compliance

The announcement was made through proper regulatory channels, with Company Secretary and Compliance Officer Sanu Kapoor signing the notification. The company emphasized that discussions during the call will be based on publicly available information, maintaining transparency standards. The filing also noted that changes may occur due to exigencies on the part of the host or company.